Posted by kinasepro on October 3, 2006
Hi Novartis, nice follow on with WO2006101783. Here’s a representative example and their Markush:
�Their latest application is a gleevec analog with a pyrrolopyrimidine hinge interaction, which looks nice enough. I wager they’re looking at a potency / selectivity angle. The added imidazo group probably brings in something like TIE2, or IKK… Think they could be a little more vague in your claims though?
>> Update. Ok, ok I guess there is more too it. I didn’t notice on the first pass but they claim to hit some Gleevec resistant strains. Good show.